Linked Data API

Show Search Form

Search Results

1128442
star this property registered interest false more like this
star this property date less than 2019-05-23more like thismore than 2019-05-23
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Cannabis: Medical Treatments more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will publish the evidence (a) his Department and (b) the Department for International Trade holds on growing a market for prescribed medicinal cannabis. more like this
star this property tabling member constituency Hemel Hempstead more like this
star this property tabling member printed
Sir Mike Penning more like this
unstar this property uin 257706 more like this
star this property answer
answer
unstar this property is ministerial correction true more like this
star this property date of answer less than 2019-06-10more like thismore than 2019-06-10
star this property answer text <p><ins class="ministerial"> <p><ins class="ministerial">The Department for International Trade and the Department of Health and Social Care are not specifically collecting data on the growth of the market for cannabis based products for medicinal use in the United Kingdom.</ins></p><p><ins class="ministerial">However, data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows growing numbers of import notifications for medicinal cannabis and the Home Office has received increased numbers of licence applications.</ins></p><p><ins class="ministerial">In addition, UK companies exporting these products and foreign companies looking to invest in the UK have full access to government support, where they have the necessary authorisations from the MHRA and Home Office and a relevant Export Licence.</ins></p></ins></p><p><del class="ministerial">An initial impact assessment was published alongside The Misuse of Drugs (Amendments) (Cannabis and Licence Fees) (England, Wales and Scotland) Regulations 2018. This can be viewed at the following link:</del></p><p><del class="ministerial"><a href="http://www.legislation.gov.uk/uksi/2018/1055/impacts" target="_blank">http://www.legislation.gov.uk/uksi/2018/1055/impacts</a></del></p><p><del class="ministerial">This set out the approach that the Government proposed to take in assessing the costs and benefits of the change in the law at a population level, with regard to the rescheduling of cannabis-based products for medicinal use (CBPM). This framework included potential savings in treatment costs, giving the example of patients with severe epilepsy for whom medicinal use of cannabis could reduce the frequency of seizures and reduce the number of related hospital admissions. This was an initial framework for assessing this policy and as we develop our knowledge in this area, both on the costs and the potential benefits, we can revisit and refine these assessments.</del></p><p><del class="ministerial">In the meantime, the National Institute for Health and Care Excellence (NICE) is developing clinical guidelines on the appropriate use of CBPM based on the best available evidence, and the National Institute for Health Research is funding further clinical research on this. More information is available at the following link:</del></p><p><del class="ministerial"><a href="https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf" target="_blank">https://www.nihr.ac.uk/funding-and-support/documents/themed-calls/cannabis-based%20products/cannabis-based-products-brief.pdf</a></del></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-10T13:18:03.37Zmore like thismore than 2019-06-10T13:18:03.37Z
star this property question first ministerially corrected
less than 2019-06-11T11:31:21.83Zmore like thismore than 2019-06-11T11:31:21.83Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property previous answer version
121340
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1528
unstar this property label Biography information for Sir Mike Penning more like this
1129191
star this property registered interest false more like this
star this property date less than 2019-06-03more like thismore than 2019-06-03
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Prescription Drugs more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how many prescriptions of (a) individual benzodiazepine drugs and (b) individual antidepressants were dispensed in the community in 2018. more like this
star this property tabling member constituency Bristol North West more like this
star this property tabling member printed
Darren Jones more like this
unstar this property uin 259400 more like this
star this property answer
answer
unstar this property is ministerial correction true more like this
star this property date of answer less than 2019-06-11more like thismore than 2019-06-11
star this property answer text <p>Information on the number of prescription items from the Prescription Cost Analysis system for benzodiazepines and antidepressants written in the United Kingdom and dispensed in the community in England, for the year 2018 can be found in the attached tables.</p><p>The data available is at prescription item level by presentation. Prescriptions are prescribed either by a paper prescription form or via an Electronic Prescription Service message. Each single item written on the form is counted as a prescription item. No information is available for those prescriptions written but not dispensed.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-11T16:51:00.313Zmore like thismore than 2019-06-11T16:51:00.313Z
star this property question first ministerially corrected
less than 2019-06-12T14:34:05.54Zmore like thismore than 2019-06-12T14:34:05.54Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property attachment
1
star this property file name PQ259400 table formatted.docx more like this
star this property title Prescription data benzodiazipines & antidepressant more like this
star this property previous answer version
122124
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4621
unstar this property label Biography information for Darren Jones more like this
1132035
star this property registered interest false more like this
star this property date less than 2019-06-13more like thismore than 2019-06-13
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading General Practitioners more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what the requirements for primary care networks to engage with the local community will be. more like this
star this property tabling member constituency Newton Abbot more like this
star this property tabling member printed
Anne Marie Morris more like this
unstar this property uin 264406 more like this
star this property answer
answer
unstar this property is ministerial correction true more like this
star this property date of answer less than 2019-06-18more like thismore than 2019-06-18
star this property answer text <p><ins class="ministerial"> <p><ins class="ministerial">Primary Care Networks (PCNs) are a new way for primary and community service organisations to work together. For PCNs to be successful they will need to work in partnership with local people and the communities they serve. Legal duties which currently apply to NHS service providers - including general practitioner practices - and commissioners around engagement and consultation will continue to be valid for PCNs.</ins></p></ins></p><p><del class="ministerial">NHS England and NHS Improvement, together with the National Institute for Health and Care Excellence, is developing a ’commercial framework’ setting out the parameters for the commercial approach for medicines in the health service in England.</del></p><p><del class="ministerial">The commercial framework will support a single, transparent, robust and integrated pricing and market access process, and is being tested with and informed through consultation with stakeholders including the Association of the British Pharmaceutical Industry.</del></p><p><del class="ministerial">In preparation for public consultation in the coming months, NHS England is actively engaging with industry trade bodies and health system partners, in the first instance, to outline progress on the development of the commercial framework. The consultation on the draft framework is anticipated to be launched in Quarter 3 2019 with consultation events to be held in Manchester and London, and implementation of the commercial framework is expected to follow.</del></p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-06-18T16:34:05.507Zmore like thismore than 2019-06-18T16:34:05.507Z
star this property question first ministerially corrected
less than 2019-06-19T08:36:30.617Zmore like thismore than 2019-06-19T08:36:30.617Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property previous answer version
123829
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4249
unstar this property label Biography information for Anne Marie Morris more like this
1141704
star this property registered interest false more like this
star this property date less than 2019-07-24more like thismore than 2019-07-24
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Mental Health Services: Children and Young People more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, how much each clinical commissioning group has spent on child and adolescent mental health services in each year since 2013. more like this
star this property tabling member constituency Harborough more like this
star this property tabling member printed
Neil O'Brien more like this
unstar this property uin 281781 more like this
star this property answer
answer
unstar this property is ministerial correction true more like this
star this property date of answer less than 2019-09-09more like thismore than 2019-09-09
star this property answer text <p>Information on spend on mental health provision for children and young people aged 0-25, by clinical commissioning group is not available prior to 2016/17. Details of spend for 2016/17, 2017/18 and 2018/19 is set out in the attached table. This includes spend on eating disorders but excludes spend on learning disabilities.</p><p>This information is included in the Mental Health Five Year Forward View Dashboard, published by NHS England, which is available at the following link:</p><table><tbody><tr><td><p><a href="https://www.england.nhs.uk/mental-health/taskforce/imp/mh-dashboard/" target="_blank">https://www.england.nhs.uk/mental-health/taskforce/imp/mh-dashboard/</a></p></td></tr></tbody></table><p> </p> more like this
star this property answering member constituency Mid Bedfordshire more like this
star this property answering member printed Ms Nadine Dorries more like this
star this property question first answered
less than 2019-09-09T17:34:25.64Zmore like thismore than 2019-09-09T17:34:25.64Z
star this property question first ministerially corrected
less than 2019-09-10T10:42:53.143Zmore like thismore than 2019-09-10T10:42:53.143Z
star this property answering member
1481
star this property label Biography information for Ms Nadine Dorries more like this
star this property attachment
1
star this property file name PQ281781 attachment formatted.xlsx more like this
star this property title CAMHS Spend since 2013 more like this
star this property previous answer version
135787
star this property answering member constituency Mid Bedfordshire more like this
star this property answering member printed Ms Nadine Dorries more like this
star this property answering member
1481
star this property label Biography information for Ms Nadine Dorries more like this
star this property tabling member
4679
unstar this property label Biography information for Neil O'Brien more like this
1127749
star this property registered interest false more like this
star this property date less than 2019-05-21more like thisremove minimum value filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading NHS: BioMarin more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the progress of talks on procuring medicines between the NHS and Bio Marin. more like this
star this property tabling member constituency Gloucester more like this
star this property tabling member printed
Richard Graham more like this
unstar this property uin 256971 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-30more like thismore than 2019-05-30
star this property answer text <p>We have made no such assessment. Discussions about commercial agreements for medicines are rightly held between NHS England as an independent body and the manufacturer concerned. The Department plays no role in such discussions.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-30T10:48:36.497Zmore like thismore than 2019-05-30T10:48:36.497Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
3990
unstar this property label Biography information for Richard Graham more like this
1127754
star this property registered interest false more like this
star this property date less than 2019-05-21more like thisremove minimum value filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Blood Diseases: Health Services more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what his timescale is for (a) implementing and (b) completing NHS England’s planned restructuring of haemoglobinopathy services; and if he will make a statement. more like this
star this property tabling member constituency Kingston upon Hull North more like this
star this property tabling member printed
Diana Johnson more like this
unstar this property uin 256972 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-06-04more like thismore than 2019-06-04
star this property answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
256973 more like this
256974 more like this
257011 more like this
star this property question first answered
less than 2019-06-04T16:13:21.643Zmore like thismore than 2019-06-04T16:13:21.643Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property attachment
1
star this property file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx more like this
star this property title FAE sickle cell NHS England table more like this
star this property tabling member
1533
unstar this property label Biography information for Diana Johnson more like this
1127755
star this property registered interest false more like this
star this property date less than 2019-05-21more like thisremove minimum value filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Sickle Cell Diseases: Health Services more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of NHS England’s planned restructuring of haemoglobinopathy services on (a) equitable access to services, (b) access to the most effective treatments, (c) access to highly specialised care and (d) quality of care in community-based settings for patients with sickle cell disease. more like this
star this property tabling member constituency Kingston upon Hull North more like this
star this property tabling member printed
Diana Johnson more like this
unstar this property uin 256973 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-06-04more like thismore than 2019-06-04
star this property answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
256972 more like this
256974 more like this
257011 more like this
star this property question first answered
less than 2019-06-04T16:13:21.707Zmore like thismore than 2019-06-04T16:13:21.707Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property attachment
1
star this property file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx more like this
star this property title FAE sickle cell NHS England table more like this
star this property tabling member
1533
unstar this property label Biography information for Diana Johnson more like this
1127756
star this property registered interest false more like this
star this property date less than 2019-05-21more like thisremove minimum value filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Sickle Cell Diseases: Health Services more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will publish impact assessments of the potential effects of NHS England’s planned restructuring of haemoglobinopathy services on treatment of (a) all haemoglobinopathies and (b) sickle cell disease. more like this
star this property tabling member constituency Kingston upon Hull North more like this
star this property tabling member printed
Diana Johnson more like this
unstar this property uin 256974 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-06-04more like thismore than 2019-06-04
star this property answer text <p>It is anticipated that NHS England’s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.</p><p>As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.</p><p>The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.</p><p>Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.</p>
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property grouped question UIN
256972 more like this
256973 more like this
257011 more like this
star this property question first answered
less than 2019-06-04T16:13:21.767Zmore like thismore than 2019-06-04T16:13:21.767Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property attachment
1
star this property file name Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx more like this
star this property title FAE sickle cell NHS England table more like this
star this property tabling member
1533
unstar this property label Biography information for Diana Johnson more like this
1127772
star this property registered interest false more like this
star this property date less than 2019-05-21more like thisremove minimum value filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Voluntary Scheme for Branded Medicines Pricing and Access more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, whether the review of the methods for the NICE Technology Appraisal Programme referred to in the 2019 voluntary scheme for branded medicines pricing and access will include support for earlier patient access to innovative medicines. more like this
star this property tabling member constituency Bolton West more like this
star this property tabling member printed
Chris Green more like this
unstar this property uin 257056 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-30more like thismore than 2019-05-30
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is in the process of scoping the review of the methods for technology appraisal and highly specialised technologies evaluations. Scoping will involve patient organisations and other relevant stakeholders, including industry. The Voluntary Scheme for Branded Medicines Pricing and Access sets out the Department’s expectation that that any future changes to NICE methods and processes would support faster adoption of the most clinically and cost effective medicines. Additional detail and more information will be made available on the NICE website in due course.</p><p>The 2019 Voluntary Scheme also states that NICE will adopt the principle of appraisal timelines for non-oncology treatments matching the faster timescales for oncology treatments, subject to the evidence base for the product being sufficiently developed to enable a NICE appraisal with the same level of rigour and certainty as would be expected currently.</p> more like this
star this property answering member constituency South Ribble more like this
star this property answering member printed Seema Kennedy more like this
star this property question first answered
less than 2019-05-30T10:52:06.847Zmore like thismore than 2019-05-30T10:52:06.847Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
4398
unstar this property label Biography information for Chris Green more like this
1127781
star this property registered interest false more like this
star this property date less than 2019-05-21more like thisremove minimum value filter
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care remove filter
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Social Prescribing more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what his Department's policy is on social prescribing. more like this
star this property tabling member constituency Totnes more like this
star this property tabling member printed
Dr Sarah Wollaston more like this
unstar this property uin 257061 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2019-05-23more like thismore than 2019-05-23
star this property answer text <p>‘Prevention is better than cure’, published by the Department in November 2018, highlighted the important role social prescribing can play in reducing people’s isolation and improving levels of activity.</p><p>As set out in the NHS Long Term Plan, NHS England has committed to deliver at least £4.5 billion of new investment in primary medical and community health services over the next five years. Part of this investment will support the recruitment of over 1,000 trained social prescribing link workers - in place by the end of 2020/21 rising further by 2023/24, with the aim that over 900,000 people are able to be referred to social prescribing schemes by then.</p><p>The Prevention document and the Long Term Plan can be found at the following links:</p><p><a href="http://www.gov.uk/government/publications/prevention-is-better-than-cure-our-vision-to-help-you-live-well-for-longer" target="_blank">www.gov.uk/government/publications/prevention-is-better-than-cure-our-vision-to-help-you-live-well-for-longer</a></p><p><a href="http://www.longtermplan.nhs.uk/publication/nhs-long-term-plan/" target="_blank">www.longtermplan.nhs.uk/publication/nhs-long-term-plan/</a></p><p><strong> </strong></p>
star this property answering member constituency Gosport more like this
star this property answering member printed Caroline Dinenage more like this
star this property question first answered
less than 2019-05-23T14:58:45.327Zmore like thismore than 2019-05-23T14:58:45.327Z
star this property answering member
4008
star this property label Biography information for Caroline Dinenage more like this
star this property tabling member
4073
unstar this property label Biography information for Dr Sarah Wollaston more like this